ANGLE PLC (LON:AGL) (OTCMKTS:ANPCY) revealed that leading European cancer centre, University Medical Centre Hamburg-Eppendorf (UKE), Germany has published results of work demonstrating that the company’s Parsortix system can be used as a liquid biopsy to investigate prediction and monitoring of therapy responses for melanoma patients.
In a statement, the AIM-listed company said the results of the study by UKE have been published in the renowned peer-reviewed medical journal, Cancers.
In the research, it added, UKE used Parsortix over a five-year period, with follow-up in some cases for three years, the results showing that Parsortix can harvest circulating tumor cells (CTCs) from some melanoma patients, where other cell surface marker dependent systems are unable to do so.
ANGLE said this development holds the potential to shift current treatment options for malignant melanoma, which is the deadliest form of skin cancer, with a global incidence of 290,000 per annum and 970,000 people living with the disease, according to Globocan 2018.
Analysis of CTCs harvested from melanoma patients opens up the potential for Parsortix's use as a companion diagnostic to select appropriate therapies and regularly monitor patients with melanoma, ensuring any potential relapse is flagged early and patients can receive the best treatment possible, the group added.
The researchers demonstrated that the presence of CTCs in a patient's blood sample -where in a previous sample they had been absent - indicated relapse earlier than standard of care imaging techniques, ANGLE said.
ANGLE's founder and chief executive, Andrew Newland, commented: "As the deadliest form of skin cancer, there is a clear need for reliable biomarkers in melanoma. Initially, these can be used in drug trials where the detection of likely responders to the drug is essential and a key commercial need for pharma companies. Ultimately there is the potential for routine clinical use as a companion diagnostic in melanoma."